What types of treatment goals or patient expectations align particularly well with your experience using tildrakizumab?
Featuring:
Updated:Aug 18, 2026
This symposium explores the diverse clinical manifestations of cutaneous lupus erythematosus (CLE) and their implications for diagnosis, prognosis, and treatment. Through expert discussion, Dr. Vleugels and Dr. Prenner will examine CLE subtypes and their associations with systemic disease, strategies for recognizing manifestations across diverse skin tones, and practical considerations for individualized treatment selection. The program will also highlight emerging clinical evidence on targeted therapies that may expand treatment options and improve outcomes for patients with CLE.2026 Congress of Clinical Rheumatology Rheum-Derm Summit: Skin Signals: Cutaneous Lupus Erythematosus Manifestations and ManagementThis activity is supported by an educational grant from Biogen.
DermInsider consists of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:Wednesday, September 9, 20268 PM ET / 5 PM PTSession 4: Progress Through Precision: Leveraging IL-13 Insights to Personalize Atopic Dermatitis CareThis activity is supported by an educational grant from Lilly.
In the first DermInsider - A Virtual Grand Rounds Series session of the year, join leading experts Dr. Bhutani and Dr. Serota for a dynamic deep dive into one of the most exciting frontiers in psoriatic disease management. Dr. Del Rosso moderates this 45-minute activity that explores the rapidly emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their potential impact beyond metabolic disease. Don't miss out on this opportunity to catch up on breakthrough insights and emerging evidence on this hot topic!“We have some really interesting data on the horizon that’s going to hopefully help more providers feel confident about using [GLP-1] medications in conjunction with their psoriasis medications that they are used to using.” – Tina Bhutani, MD MASBest of FC25: GLP-1RAs in Psoriasis – Catching Up on The ScienceThis activity is supported by an educational grant from Lilly.
Got a few minutes? Join our expert faculty for their rapid-fire tips on getting started with GLP-1 receptor agonists for patients with psoriasis and obesity.“When we are treating patients with obesity and psoriasis in weight management, really focus on the health gains. It’s not about what people are losing, it’s about what they are gaining in this process.” – Angela Fitch, MDPlease visit the “Educational Resources” page to access the handouts developed by faculty on GLP's in psoriatic disease mentioned in this activity.This activity is supported by an educational grant from Lilly.